Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

676 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines.
Zhao W, Li J, Chen MM, Luo Y, Ju Z, Nesser NK, Johnson-Camacho K, Boniface CT, Lawrence Y, Pande NT, Davies MA, Herlyn M, Muranen T, Zervantonakis IK, von Euw E, Schultz A, Kumar SV, Korkut A, Spellman PT, Akbani R, Slamon DJ, Gray JW, Brugge JS, Lu Y, Mills GB, Liang H. Zhao W, et al. Among authors: herlyn m. Cancer Cell. 2020 Dec 14;38(6):829-843.e4. doi: 10.1016/j.ccell.2020.10.008. Epub 2020 Nov 5. Cancer Cell. 2020. PMID: 33157050 Free PMC article.
Learning the ABCs of melanoma-initiating cells.
Zabierowski SE, Herlyn M. Zabierowski SE, et al. Among authors: herlyn m. Cancer Cell. 2008 Mar;13(3):185-7. doi: 10.1016/j.ccr.2008.02.015. Cancer Cell. 2008. PMID: 18328422 Free article.
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K.
Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, Wubbenhorst B, Xu X, Gimotty PA, Kee D, Santiago-Walker AE, Letrero R, D'Andrea K, Pushparajan A, Hayden JE, Brown KD, Laquerre S, McArthur GA, Sosman JA, Nathanson KL, Herlyn M. Villanueva J, et al. Among authors: herlyn m. Cancer Cell. 2010 Dec 14;18(6):683-95. doi: 10.1016/j.ccr.2010.11.023. Cancer Cell. 2010. PMID: 21156289 Free PMC article.
Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.
Krepler C, Xiao M, Sproesser K, Brafford PA, Shannan B, Beqiri M, Liu Q, Xu W, Garman B, Nathanson KL, Xu X, Karakousis GC, Mills GB, Lu Y, Ahmed TA, Poulikakos PI, Caponigro G, Boehm M, Peters M, Schuchter LM, Weeraratna AT, Herlyn M. Krepler C, et al. Among authors: herlyn m. Clin Cancer Res. 2016 Apr 1;22(7):1592-602. doi: 10.1158/1078-0432.CCR-15-1762. Epub 2015 Dec 16. Clin Cancer Res. 2016. PMID: 26673799 Free PMC article.
Targeting Notch enhances the efficacy of ERK inhibitors in BRAF-V600E melanoma.
Krepler C, Xiao M, Samanta M, Vultur A, Chen HY, Brafford P, Reyes-Uribe PI, Halloran M, Chen T, He X, Hristova D, Liu Q, Samatar AA, Davies MA, Nathanson KL, Fukunaga-Kalabis M, Herlyn M, Villanueva J. Krepler C, et al. Among authors: herlyn m. Oncotarget. 2016 Nov 1;7(44):71211-71222. doi: 10.18632/oncotarget.12078. Oncotarget. 2016. PMID: 27655717 Free PMC article.
A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers.
George E, Kim H, Krepler C, Wenz B, Makvandi M, Tanyi JL, Brown E, Zhang R, Brafford P, Jean S, Mach RH, Lu Y, Mills GB, Herlyn M, Morgan M, Zhang X, Soslow R, Drapkin R, Johnson N, Zheng Y, Cotsarelis G, Nathanson KL, Simpkins F. George E, et al. Among authors: herlyn m. JCI Insight. 2017 Jan 12;2(1):e89760. doi: 10.1172/jci.insight.89760. JCI Insight. 2017. PMID: 28097235 Free PMC article.
Oncogenic RAS Regulates Long Noncoding RNA Orilnc1 in Human Cancer.
Zhang D, Zhang G, Hu X, Wu L, Feng Y, He S, Zhang Y, Hu Z, Yang L, Tian T, Xu W, Wei Z, Lu Y, Flaherty KT, Zhong X, Mills GB, Gimotty PA, Xu X, Herlyn M, Zhang L. Zhang D, et al. Among authors: herlyn m. Cancer Res. 2017 Jul 15;77(14):3745-3757. doi: 10.1158/0008-5472.CAN-16-1768. Epub 2017 May 4. Cancer Res. 2017. PMID: 28473531 Free PMC article.
676 results